Fisons assaults "undervalued" Rhone-Poulenc Rorer (RPR) bid:
This article was originally published in Clinica
UK pharmaceutical company Fisons argues in its defence document countering a hostile bid that the Rhone-Poulenc Rorer offer undervalues the sales potential of its asthma medicine delivery devices. RPR's offer stands at 240 pence per share but could be increased by about 20 pence. Fisons' CEO Stuart Wallis says it would require a substantial increase in the offer to tempt Fisons to consider it seriously.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.